37 356

Cited 0 times in

Are there any ethnic differences in molecular predictors of erlotinib efficacy in advanced non-small cell lung cancer?

Ahn, MJ; Park, BB; Ahn, JS; Kim, SW; Kim, HT; Lee, JS; Kang, JH; Cho, JY; Song, HS; Park, SH; Sohn, CH; Shin, SW; Choi, JH; Ki, CS; Park, CK; Holmes, AJ; Jänne, PA; Park, K
Clinical cancer research : an official journal of the American Association for Cancer Research, 14(12):3860-3866, 2008
Journal Title
Clinical cancer research : an official journal of the American Association for Cancer Research
PURPOSE: This study investigated possible molecular predictors of outcome in Korean patients with advanced non-small cell lung cancer treated with erlotinib.

EXPERIMENTAL DESIGN: One hundred and twenty patients received erlotinib and were followed prospectively. Ninety-two tissue samples were analyzed for epidermal growth factor receptor (EGFR) gene mutations (exons 18, 19, and 21), 88 for EGFR gene amplification by real-time PCR, and 75 for EGFR protein expression by immunohistochemistry.

RESULTS: The overall tumor response rate was 24.2% (complete response, 4; partial response, 25) with 56.7% of disease control rate. With a median follow-up of 23.6 months, the median time to progression (TTP) was 2.7 months and the median overall survival was 12.9 months. EGFR gene mutations were found in 26.1% (24 of 92), EGFR gene amplification in 40.9% (36 of 88), and EGFR protein expression in 72% (54 of 75). There was a strong association between EGFR gene mutations and gene amplification (gamma = 0.241). Patients with EGFR gene mutations or gene amplification showed both better response rate (58.3% versus 16.2%, P < 0.001; 41.7% versus 17.3%, P = 0.012) and TTP (8.6 versus 2.5 months, P = 0.003; 5.8 versus 1.8 months, P < 0.001) and overall survival (not reached versus 10.8 months, P = 0.023; not reached versus 10.1 months, P = 0.033). By multivariate analysis, EGFR gene mutation was the only significant molecular predictor for TTP (hazard ratio, 0.47; 95% confidence interval, 0.25-0.89).

CONCLUSIONS: Our findings indicate that EGFR gene mutation is a more predictive marker for improved TTP than EGFR gene amplification in erlotinib-treated Korean non-small cell lung cancer patients. Prospective studies from diverse ethnic backgrounds are required to determine the exact role of these molecular markers.
MeSH terms
AdultAgedAged, 80 and overAntineoplastic Agents/administration & dosageAntineoplastic Agents/therapeutic useCarcinoma, Non-Small-Cell Lung/diagnosis*Carcinoma, Non-Small-Cell Lung/drug therapy*Carcinoma, Non-Small-Cell Lung/ethnologyCarcinoma, Non-Small-Cell Lung/geneticsDNA Mutational AnalysisDisease ProgressionDisease-Free SurvivalEthnic Groups/genetics*FemaleGenes, erbB-1HumansLung Neoplasms/diagnosis*Lung Neoplasms/drug therapy*Lung Neoplasms/ethnologyLung Neoplasms/geneticsMaleMiddle AgedMutation/physiologyQuinazolines/administration & dosageQuinazolines/therapeutic use*Time FactorsTreatment OutcomeTumor Markers, Biological/genetics*
Appears in Collections:
Journal Papers > School of Medicine / Graduate School of Medicine > Hematology-Oncology
AJOU Authors
최, 진혁
Full Text Link
RIS (EndNote)
XLS (Excel)


해당 아이템을 이메일로 공유하기 원하시면 인증을 거치시기 바랍니다.

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.